Guest: Carrie Freeman

In this episode, we sit down with Carrie Freeman, CEO of Eden Radioisotopes, to explore the intersection of deep science, commercialization, and leadership. After spending 15 years at Intel and serving as a multi-time CEO, Carrie has built a career around transforming breakthrough technologies into scalable businesses.

We discuss what it takes to commercialize innovations emerging from national laboratories, the resurgence of the nuclear industry, and why private capital is increasingly driving the next generation of nuclear technologies. Carrie also shares her perspective on leadership transitions, fundraising for long-horizon ventures, and how organizations can remain focused on human impact while operating at the cutting edge of science.

Carrie reflects on the most important lessons learned during her tenure at Intel and explains how principles of operational excellence, precision, and scalability transfer directly into the highly regulated nuclear industry.

As a multi-time CEO, Carrie shares her framework for entering an organization, building trust quickly, assessing priorities, and establishing momentum without disrupting existing strengths.

Moving a breakthrough technology from a national laboratory into the private sector presents unique challenges. Carrie discusses the critical steps required to bridge the gap between scientific innovation and market adoption.

The conversation explores why nuclear technologies are experiencing renewed interest and how private-sector companies are accelerating innovation across healthcare, energy, and national security applications.

Rather than viewing regulation solely as a barrier, Carrie explains how companies can leverage regulatory expertise to create durable competitive moats and strengthen market positioning.

Deep-tech ventures often require patient capital and extended development timelines. Carrie shares insights on communicating vision, maintaining investor confidence, and aligning expectations for long-term value creation.

With the company tagline "Precision Science, Human Impact," Carrie discusses how leaders can keep teams connected to the real-world impact of their work while navigating complex scientific and technical challenges.

Carrie Freeman is the CEO of Eden Radioisotopes and an experienced technology executive with leadership experience spanning semiconductors, advanced manufacturing, and nuclear science. Her career includes 15 years at Intel and multiple CEO roles focused on commercializing breakthrough technologies and scaling innovation-driven organizations.

Eden Radioisotopes develops advanced nuclear technologies that support applications across healthcare, energy, and security. The company's mission is captured in its guiding principle: "Precision Science. Human Impact."

Learn more: https://edenrad.com/

LinkedIn: https://www.linkedin.com/in/carrie-freeman/

Disclaimer: The views expressed in this podcast are for informational purposes only. They do not constitute financial or legal advice, nor do they necessarily reflect the views of Finalis Inc. or Finalis Securities LLC, Member FINRA/SIPC.

#Podcast

#BusinessPodcast

#CEO

#FounderJourney

#NuclearIndustry

#NuclearEnergy

#NuclearInnovation

#Radioisotopes

#DeepTech

#Commercialization

#TechnologyTransfer

#NuclearMedicine

#EnergyInnovation

#AdvancedManufacturing